Stock Events

Stock Events

Pieris Pharmaceuticals 

0
24
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q1 2026
Q2 2026
Next
-1.54
-1.29
-1.05
-0.8
Expected EPS
-1.5426766944
Actual EPS
N/A

Financials

222.78%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.59MRevenue
10.23MNet Income

Analyst Ratings

184.64Average Price Target
The highest estimate is 204.88.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PI6.STU. It's not an investment recommendation.
Microsoft
3
MSFT
Amazon
3
AMZN
NVIDIA
3
NVDA
AMD
3
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on immunology and inflammation, areas where Pieris also operates.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm with a broad portfolio that includes treatments in areas overlapping with Pieris' interests, such as respiratory diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in the development of therapies for serious diseases, including cystic fibrosis, a target area for Pieris' respiratory focus.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics, in areas that can compete with Pieris' pipeline.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology, autoimmune and rare diseases, but its expansion into new therapeutic areas can position it as a competitor to Pieris.
Moderna
MRNA
Mkt Cap55.09B
Moderna, known for its mRNA technology, is expanding its pipeline into diverse therapeutic areas, potentially competing with Pieris' protein engineering approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapeutics, offering a different but competing approach to treating diseases targeted by Pieris.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk is a global healthcare company with a strong focus on protein-based therapies for diabetes and other serious chronic conditions, overlapping with Pieris' technology.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global biopharmaceutical company working in various therapeutic areas, including respiratory diseases, where it competes with Pieris.

About

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Show more...
CEO
Wesley H. Kaupinen
Employees
29
Country
United States
ISIN
US7207951036

Listings

MU
DE
PI60.MU
STU
DE
PI60.STU
MU
DE
PI6.MU
STU
DE
PI6.STU

0 Comments

Share your thoughts

FAQ

What is Pieris Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Pieris Pharmaceuticals stocks are traded under the ticker PI6.STU.
When is the next Pieris Pharmaceuticals earnings date?▼
Pieris Pharmaceuticals is going to release the next earnings report on November 17, 2026.
What were Pieris Pharmaceuticals earnings last quarter?▼
PI6.STU earnings for the last quarter are -1.32 EUR per share, whereas the estimation was -1.02 EUR resulting in a -29.55% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Pieris Pharmaceuticals revenue for the last year?▼
Pieris Pharmaceuticals revenue for the last year amounts to 4.59M EUR.
What is Pieris Pharmaceuticals net income for the last year?▼
PI6.STU net income for the last year is 10.23M EUR.
How many employees does Pieris Pharmaceuticals have?▼
As of September 05, 2026, the company has 29 employees.
In which sector is Pieris Pharmaceuticals located?▼
Pieris Pharmaceuticals operates in the Health & Wellness sector.
When did Pieris Pharmaceuticals complete a stock split?▼
The last stock split for Pieris Pharmaceuticals was on April 23, 2024 with a ratio of 1:80.
Where is Pieris Pharmaceuticals headquartered?▼
Pieris Pharmaceuticals is headquartered in WAYNE, United States.